CBD–Ibuprofen Oral Composition for Rapid, Sustained Analgesia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing oral pain relievers face challenges such as delayed onset of action, gastrointestinal side effects, liver or kidney toxicity, and risks of dependency or abuse, while existing cannabinoid-based methods have variable effectiveness and side effects due to bioavailability and individual variability.

Innovation Solution

A composition combining cannabidiol isolate and ibuprofen with excipients like starch, sucrose, and polyvinylpyrrolidone, formulated for rapid or controlled release, optimizing drug delivery and efficacy for pain relief.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If traditional oral analgesics (NSAIDs, ibuprofen) are used, then pain relief is provided, but delayed onset of action and gastrointestinal side effects occur

Engineering Contradiction:

Improveonset of actionVSAvoidgastrointestinal side effects

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent combines cannabidiol (CBD) with ibuprofen in a single oral composition to leverage the rapid absorption and analgesic properties of CBD while maintaining the anti-inflammatory effects of ibuprofen. This combination allows for faster onset of pain relief through CBD's rapid bioavailability while potentially reducing the required dose of ibuprofen, thereby minimizing gastrointestinal side effects.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical formulation containing both CBD and ibuprofen along with excipients designed to optimize delivery. The composite nature of this formulation enables synergistic effects where CBD's rapid onset complements ibuprofen's sustained anti-inflammatory action, achieving both speed and safety objectives.

Inventive Principle:

Principle #40Composite materials

2Reliability

If opioids are used for pain management, then effective pain relief is achieved, but risks of dependency and abuse increase

Engineering Contradiction:

Improvepain relief effectivenessVSAvoiddependency and abuse risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent positions the CBD-ibuprofen composition as a non-addictive alternative to opioids for managing acute and chronic pain. By using CBD, a substance with no known abuse potential, combined with ibuprofen for sustained effect, the formulation provides reliable pain relief without the dependency risks associated with opioid medications.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If existing cannabinoid-based pain relief methods are used, then some pain relief is provided, but variable effectiveness and side effects occur due to bioavailability issues

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidside effects and variability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent optimizes the CBD content in the formulation to comprise between 2% to 35% by dry weight of the composition, a specific parameter range determined to achieve reliable and consistent analgesic effects. This controlled parameter specification, combined with standardized CBD isolate or distillate materials, ensures consistent bioavailability and reduces the variability and side effects associated with unstandardized cannabinoid products.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250302785A1Oral pain reliever composition, pharmaceutical formulation, and process for making composition and formulation including cannabidiol isolate with select active ingredients

Publication Date: 2025.10.02 CAVENDER MICHAEL

AI summary

A chemical composition for an oral pharmaceutical product is described having a therapeutically effective amount of one or more active pharmaceutical ingredients (API) including ibuprofen in combination with a cannabidiol (CBD) isolate.